Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

#Agios is planning to file its #sicklecelldisease (SCD) candidate #mitapivat with the #FDA under the #acceleratedpathway, based on feedback from the US regulator at a recent meeting.

The Economic Revolution of AI Development: From Unsustainable Subscription Models to Value-Aligned Commission-Based Ecosystems. The Economic Revolution of AI Development: From Unsustainable Subscription Models to Value-Aligned Commission-Based Ecosystems COMPREHENS...

better-experience.blogspot.com/2026/01/the-...

#MITAPIVAT
aepiot.ro/advanced-sea...
aepiot.com

Mixed Results for Mitapivat in Sickle Cell Disease Trial Topline results from the RISE UP phase 3 trial demonstrated that mitapivat significantly improved hemoglobin response in patients with sickle cell disease.

Topline results were announced from a phase 3 trial evaluating #mitapivat, an oral pyruvate kinase activator, in patients with #sickleCellDisease.

https://bit.ly/4pABm8v